In Vivo Contract Research Organization Market Insights Highlight Segment Expansion And Market Leadership

The in vivo contract research organization (CRO) sector is poised for significant expansion as the demand for efficient drug development and advanced research models grows. With increasing adoption of cutting-edge technologies and rising regulatory requirements, this market is set to experience substantial gains over the coming years. Let's explore the market's size, driving forces, key players, emerging trends, and segmentation insights to understand its evolving landscape.

Projected Market Value and Growth Trajectory of the In Vivo Contract Research Organization Market
The in vivo contract research organization market is forecasted to expand robustly, reaching a value of $7.77 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 8.1%, reflecting strong momentum. Several factors contribute to this positive outlook, including the rising need for accelerated drug development timelines, increasing utilization of sophisticated in vivo disease models, and the flourishing research in oncology and rare diseases. Additionally, the expanding use of AI-powered preclinical analytics and heightened regulatory scrutiny related to safety data are significant growth drivers. Key trends anticipated to shape the market encompass a surge in outsourcing preclinical research tasks, growing demand for specialized disease models, wider adoption of GLP-compliant toxicology studies, expansion of integrated preclinical services, and a greater emphasis on ensuring data quality and reproducibility.

The in vivo contract research organization market size has grown strongly in recent years. It will grow from $5.23 billion in 2025 to $5.68 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to increasing pharmaceutical r&d spending, expansion of biotechnology pipelines, growing complexity of drug development, increased regulatory requirements for preclinical data, availability of advanced animal models.

Download a free sample of the in vivo contract research organization market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25790&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Primary Companies Influencing the In Vivo Contract Research Organization Market
A range of leading companies dominate this market, offering diverse services and innovative solutions. Notable players include Thermo Fisher Scientific Inc, Labcorp Drug Development Inc, Eurofins Scientific SE, WuXi AppTec, Charles River Laboratories International Inc, Evotec SE, GemPharmatech Co Ltd, BIOQUAL Inc, Crown Bioscience Inc, PsychoGenics Inc, Janvier Labs SAS, Taconic Bioscience Inc, Xentech SAS, Altogen Labs Inc, AniLocus Inc, Pharmaron Beijing Co Ltd, Southern Research Institute, SRI International, Envigo RMS LLC, Horizon Discovery Group plc, Inotiv Inc, and GenScript ProBio.

Strategic Acquisition Highlights Enhancing Market Presence
In a notable development in September 2024, the China-based PharmaLegacy Laboratories Co. Ltd., specializing in preclinical pharmacology contract research, acquired BTS Research for an undisclosed amount. This move is aimed at broadening PharmaLegacy's preclinical service portfolio and establishing a strategic laboratory foothold in North America, enhancing its ability to serve global biopharmaceutical clients more efficiently. BTS Research Inc., headquartered in the United States, provides both in vitro and in vivo research programs, making the acquisition a complementary fit for PharmaLegacy's expansion objectives.

View the full in vivo contract research organization market report:
https://www.thebusinessresearchcompany.com/report/in-vivo-contract-research-organization-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Innovative Trends Shaping the Future of In Vivo Contract Research Organizations
Market leaders are increasingly focusing on innovative programs designed to propel next-generation therapeutic development and support early clinical research stages. One such initiative is the advanced therapy incubator program, which offers emerging biotech companies resources, mentorship, and infrastructure to accelerate the creation of advanced therapies, including gene, cell, and RNA-based treatments.

For example, in April 2025, Charles River Laboratories International Inc., a major US pharmaceutical firm, launched its first advanced therapy incubator cohort. This program aims to assist early-stage biotech firms by providing access to Charles River's scientific expertise, cutting-edge lab facilities, and tailored in vivo models. These resources enable participants to quickly generate proof-of-concept data and validate therapeutic candidates in a real-world preclinical environment. Ultimately, this effort helps reduce the time needed to reach clinical trials and increases the probability of regulatory approval, effectively bridging academic innovation and clinical development in the advanced therapies space.

Breakdown of Market Segments and Their Forecasts in the Global In Vivo Contract Research Organization Market
This report segments the in vivo contract research organization market as follows:

1) By Type:
- Rodent Based
- Non-Rodent Based

2) By Type of Service:
- Translational and IND-Enabling In Vivo Studies
- Preclinical Services
- Post-Approval Nonclinical Safety and Mechanistic Studies

3) By Good Laboratory Practice Type:
- Good Laboratory Practice Toxicology
- Non Good Laboratory Practice

4) By Application Area:
- Oncology
- Cardiovascular Diseases
- Infectious Diseases
- Neurological Disorders
- Other Applications

5) By End User:
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic and Research Institutes
- Government and Regulatory Bodies

Detailed Subcategories Within Main Segments
Rodent-based models are further divided into mice models, rat models, genetically engineered rodents, immunodeficient rodents, and humanized rodents. Non-rodent-based models include canine models, non-human primate models, swine models, rabbit models, and zebrafish models. This detailed classification supports a comprehensive understanding of the diverse research models employed within the in vivo CRO market.

New analytical features added to our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.